PF 06826647

Drug Profile

PF 06826647

Alternative Names: PF-06826647

Latest Information Update: 16 Aug 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Pfizer
  • Class Anti-inflammatories; Antipsoriatics
  • Mechanism of Action Undefined mechanism
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase I Plaque psoriasis

Most Recent Events

  • 14 Jul 2017 Phase-I clinical trials in Plaque psoriasis in USA (PO) (NCT03210961)
  • 12 Jul 2017 Pfizer plans a phase I trial of PF 06826647 for Plaque psoriasis (PO) in July 2017 (NCT03210961)
  • 12 Jul 2017 Preclinical trials in Plaque psoriasis in USA (PO, Tablet, Suspension) (NCT03210961)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top